`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`________________
`
`PFIZER INC.,1
`Petitioner,
`
`v.
`
`NOVO NORDISK A/S,
`Patent Owner.
`________________
`
`IPR2020-003242
`
`Patent 8,114,833 B2
`__________________
`
`PATENT OWNER AND PETITIONER PFIZER INC.’S JOINT REQUEST
`TO TREAT SETTLEMENT AGREEMENT AS BUSINESS
`CONFIDENTIAL INFORMATION PURSUANT TO 35 U.S.C. § 317
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`1 The proceeding has been terminated as to the original petitioner, Mylan
`Institutional LLC. Paper 67.
`2 IPR2020-01252 has been joined with this proceeding.
`
`
`
`Pursuant to 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74(c), Petitioner Pfizer Inc.
`
`(“Pfizer”) and Patent Owner Novo Nordisk A/S (“Novo Nordisk”) jointly request
`
`that a true copy of their Settlement Agreement, filed concurrently as Exhibit 2102,
`
`be treated as business confidential information, and be kept separate from the file of
`
`IPR2020-00324 involving U.S. Patent No. 8,114,833. Concurrently with this
`
`Request, Pfizer and Novo Nordisk are filing a Joint Motion to Terminate due to the
`
`settlement between Pfizer and Novo Nordisk.
`
`Specifically, as the parties consider the Settlement Agreement to contain
`
`highly sensitive business confidential information that would substantially harm
`
`their business interests if publicly disclosed, Pfizer and Novo Nordisk hereby jointly
`
`request that the Settlement Agreement be kept as a separate paper to be made
`
`available only as provided in 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74(c). The
`
`Settlement Agreement has been filed for access by the “Board Only.”3 Pfizer and
`
`Novo Nordisk request that the Settlement Agreement remain accessible only to the
`
`Board, and not be made available to other parties to this proceeding. Pfizer and
`
`Novo Nordisk further jointly request that the Board order that in the event a person
`
`or entity makes a written request, as stated in 37 C.F.R. §42.74(c)(1)-(2), for access
`
`
`3 Petitioner Mylan Institutional LLC is not a party to the Settlement Agreement.
`Petitioner Mylan Institutional LLC has not been provided a copy of the Settlement
`Agreement.
`
`
`
`1
`
`
`
`to the Settlement Agreement, that any such written request be served upon Pfizer
`
`and Novo Nordisk on the day the written request is provided to the Board.
`
`
`
`Dated: June 18, 2021
`
`
`/Jeffrey J. Oelke/
`
`Jeffrey J. Oelke (Reg. No. 37,409)
`joelke@fenwick.com
`Ryan P. Johnson
`ryan.johnson@fenwick.com
`Laura T. Moran
`laura.moran@fenwick.com
`Fenwick & West LLP
`902 Broadway, Suite 14
`New York, NY 10010
`Telephone: (212) 430-2600
`
`
`Attorneys for Novo Nordisk A/S
`
`
`
`
`
`
`
`
`
`
` /Michael W. Johnson/
`
`Thomas J. Meloro (Reg. No. 33,538)
`Michael W. Johnson (Reg. No. 63,731)
`Willkie Farr & Gallagher LLP
`787 Seventh Avenue
`New York, NY 10019
`Telephone: (212) 728-8428
`Fax: (212) 728-8111
`tmeloro@willkie.com
`mjohnson1@willkie.com
`amoore@willkie.com
`mao-ny@willkie.com
`
`Attorneys for Pfizer Inc.
`
`
`
`2
`
`
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 C.F.R. § 42.6(e), I hereby certify that on June 18, 2021, the
`
`foregoing document is being served by filing this document through the Patent Trial
`
`and Appeal Board End to End System, as well as delivering a copy via electronic
`
`mail upon the following attorneys of record for the Petitioner:
`
`
`Thomas J. Meloro (Reg. No. 33,538)
`Michael W. Johnson (Reg. No. 63,731)
`Willkie Farr & Gallagher LLP
`787 Seventh Avenue
`New York, NY 10019
`Telephone: (212) 728-8428
`Fax: (212) 728-8111
`tmeloro@willkie.com
`mjohnson1@willkie.com
`amoore@willkie.com
`mao-ny@willkie.com
`
`
`
`
`Date: June 18, 2021
`
`
`Respectfully submitted,
`
`
`
`/Jeffrey J. Oelke/
`Jeffrey J. Oelke (Reg. No. 37,409)
`Lead Counsel
`
`
`
`
`
`
`
`
`
`
`
`3
`
`